Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: Wright Reports
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mayne Pharma Group Ltd Announces FDA Approval Of New 200mg Doryx Tablet

Thursday, 11 Apr 2013 09:04pm EDT 

Mayne Pharma Group Ltd announced that the US Food and Drug Administration (FDA) has approved a 200mg strength of Doryx (doxycycline hyclate) Delayed-Release Tablet. Warner Chilcott, the Company’s marketing and distribution partner of Doryx in the US, is expected to commence launch of this product by July 2013. Doryx Delayed-Release Tablets are a tetracycline-class oral antibiotic. 

Company Quote

-0.0050 -0.57%
28 Jul 2014